Small biotech CureDM LLC's approach to treating diabetes by stimulating the body's production of insulin-producing islet cells might be months away from the clinic, but it's already sparked the interest of big pharma, landing the firm a potential $335 million deal with Sanofi-Aventis. (BioWorld Today) Read More
